Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

Figure 2

Comparison of echocardiographic and hemodynamic parameters between the control and experimental groups following treatment with SLJ: (a, b) M-mode echocardiographic and hemodynamic images for each group; (c) cardiac systolic functions indicated by EF, FS, LVIDd, and LVIDs were compared among different groups; and (d) comparison of LVSP, LVEDP, +dp/dtmax, and −dp/dtmax hemodynamic values among different groups after treatment with SLJ. Data are expressed as the mean ± SE. n = 8. and vs. the control group. and vs. the CHF group. SJL, Shenlijia; EF, ejection fraction; FS, shortening fraction; LVIDd, left ventricular end-diastolic internal diameter; LVIDs, left ventricular end-systolic internal diameter; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; +dp/dtmax, maximum pressure positive velocity; −dp/dtmax, maximum pressure negative velocity; and CHF, chronic heart failure.

(a)

(b)

(c)

(d)

(e)